Laurus Labs Ltd

Laurus Labs announced that the 20th Annual General Meeting(AGM) of the company will be held on 26 June 2025.Powered by Capital Market - Live

Revenue from operations jumped 19.49% YoY to Rs 1,720.30 crore in Q4 FY25. Profit before tax (PBT) soared 191.17% to Rs 312.34 crore during the quarter ended 31st March 2025. EBITDA stood at Rs 477 crore in Q4 FY25, recording growth of 84%, as compared with Rs 259 crore in Q4 FY24. It includes one-time gain of Rs 59 crore from sale of land in 4Q FY25. EBITDA margin expanded to 27.7% in Q4 FY25 as against 18% in Q4 FY24. Revenue from CDMO segment jumped 85% to Rs 490 crore in Q4 FY25 as compared with Rs 265 crore in Q4 FY24. In Q4 FY25, revenue from small molecules jumped 95% YoY to Rs 461 crore, driven by several mid-to-late stage NCE deliveries and steady increase in sales from new manufacturing assets. While revenue from Bio business remained flat YoY at Rs 29 crore during the quarter. Revenue from generics business rose 5% to Rs 1,230 crore during the quarter as compared with Rs 1,175 crore in Q4 FY24. Revenue from API business declined 8% YoY to Rs 686 crore in Q4 FY25, while revenue from Finished Dosages Form (FDF) climbed 27% YoY to Rs 544 crore during the quarter. The company said that multiple integrated CMO contract signed, supplies started. FDF manufacturing lines expansion on track ' coming online by Dec-25. 'Continued investments in growth projects with CAPEX at 12% of Revenue to support long term growth' the company stated in exchange filing. On financial year basis, the company's consolidated net profit surged 123.18% to Rs 358.32 crore in FY25 as compared with Rs 160.55 crore in FY24. Revenue from operations jumped 10.18% to Rs 5,553.96 crore in FY25 as against Rs 5,040.83 crore in FY24, driven by robust demand environment for the company's CDMO offering and higher FDF sales. Satyanarayana Chava, founder 'Our business remains well positioned to evolve into a well-diversified CMO/CDMO company with promising pipeline, enabling several technology platforms and commercial excellence, thanks to team commitment to the unified vision of delivering high quality integrated solution and securing our long-term growth potential.' V V Ravi Kumar, executive director 'Despite the ongoing macroeconomic challenges, we have witnessed high level of demand for our offerings. For Q4, we delivered Rs 1,720 crore in revenues, growth of 19% and Rs 477 crore EBITDA grew by 84%, resulting in 27.7% margin. Gross margins remained healthy at 55% due to favorable CDMO mix and process optimization measures. The fundamentals of our business remain healthy. Overall FY25 results, we have delivered revenues of Rs 5,554 crore, representing 10% growth and EBITDA stood at Rs 1,115 crore, growth of 40%. The EBITDA margin of 20.1% has substantially improved, supported by continuing operating leverage within CDMO business. Going ahead, we remain confident in our growth expectations as we look forward to execute on long lead programs, new assets ramp up with revenue increasing over FY25 with continued focus on operational excellence. Our capital allocation strategy remain unchanged, prioritizing investments into high value business opportunities.' Meanwhile, the company's board approved a 2nd interim dividend of Rs 0.80 per share of Rs 2 each for FY25. The company has fixed May 09, 2025 as the record date for the said dividend. The amount will be paid on or after May 20, 2025. Laurus Labs is a research-driven pharmaceutical manufacturing organization, it has been developing and assisting its client organizations to succeed in innovative medicines that globally enhance the health outcomes for patients. It has three business divisions Generics (API+FDF), CDMO (Synthesis) and Bio. The counter shed 0.51% to end at Rs 647.15 on the BSE.Powered by Capital Market - Live

Laurus Labs announced that the Board of Directors of the Company at its meeting held on 24 April 2025, inter alia, have recommended the 2nd interim dividend of Rs 0.8 per equity Share (i.e. 40%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Laurus Labs rose 209.05% to Rs 233.67 crore in the quarter ended March 2025 as against Rs 75.61 crore during the previous quarter ended March 2024. Sales rose 19.49% to Rs 1720.30 crore in the quarter ended March 2025 as against Rs 1439.67 crore during the previous quarter ended March 2024. For the full year,net profit rose 123.18% to Rs 358.32 crore in the year ended March 2025 as against Rs 160.55 crore during the previous year ended March 2024. Sales rose 10.18% to Rs 5553.96 crore in the year ended March 2025 as against Rs 5040.83 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales1720.301439.67 19 5553.965040.83 10 OPM %24.4516.77 -19.0015.42 - PBDT422.77209.52 102 914.38620.94 47 PBT312.34107.27 191 484.29236.36 105 NP233.6775.61 209 358.32160.55 123 Powered by Capital Market - Live

Laurus Labs will hold a meeting of the Board of Directors of the Company on 24 April 2025.Powered by Capital Market - Live

The strategic move will enable Laurus Labs to access 25.53 MW of renewable wind and solar energy, which aligns with regulatory requirements under Indian Electricity Laws and government policies for captive consumption of power. The investment is aimed at reducing electricity costs, ensuring a reliable green power supply, and obtaining carbon credits, thus contributing to the company's environmental, social, and governance (ESG) objectives. Kurnool Renewables is engaged in the production of renewable energy, primarily from solar and wind sources. Laurus Labs' investment will support the development of the renewable power project, which will be used for captive consumption. This acquisition is expected to provide benefits such as reduced energy costs, enhanced energy security, and increased operational stability along with potential environmental advantages. The equity shares will be subscribed at an issue price determined by Kurnool Renewables, with a total investment of up to Rs 35 crore. The payment will be made in cash in three stages: 30% within 30 days from the execution of agreements, 40% upon placing orders for major equipment, and the remaining 30% upon receipt of major equipment at the project site. The acquisition does not fall within the purview of a related party transaction. In addition, Laurus Labs' board has approved the re-appointment of V.V. Ravi Kumar as the Executive Director and Chief Financial Officer (CFO) of the company for a period of two years, effective from 1 April 2025, subject to shareholder approval. V. V. Ravi Kumar is the executive director and chief financial officer of Laurus Labs Limited, bringing over three decades of rich experience, and especially two decades in Laurus itself, in finance, strategy, and corporate leadership. A qualified cost accountant from the Institute of Cost and Works Accountants of India, he plays a pivotal role in steering Laurus Labs toward sustainable growth and excellence. As a key leader at Laurus Labs, Mr. Ravi Kumar oversees critical business functions, including finance, information technology, mergers & acquisitions, strategic alliances, human resources, etc. He does not have any inter-se relationship with other directors of the company. The board also approved the re-appointment of Dr. Satyanarayana Chava as executive director and CEO for five years, starting 1, April 2025, subject to shareholder approval. Dr. Chava, the founder and CEO of Laurus Labs, has more than 30 years of experience in the pharmaceutical industry, with around 20 years at Laurus Labs. He holds a Ph.D. in chemistry from Andhra University and has been instrumental in positioning the company as a leader in both domestic and international markets. Dr. Satyanarayana Chava is the father of Mr. Krishna Chaitanya Chava and Mrs. Soumya Chava, executive directors of the company. Laurus Labs is a fully integrated pharmaceutical and biotechnology company with a leadership position in generic active pharmaceutical ingredients (APIs) and a major focus on anti-retroviral and oncology drugs, cardiovascular, gastro, and hepatitis C therapeutics. The company also develops and manufactures oral solid formulations and provides contract research and manufacturing services (CRAMS) to global pharma companies. The company's consolidated net profit soared 298.9% to Rs 92.30 crore in Q3 FY25 as against Rs 23.14 crore posted in Q3 FY24. Net sales jumped 18.4% YoY to Rs 1,415.05 crore in the quarter ended 31 December. The counter shed 0.76% to Rs 613.50 on the BSE. Powered by Capital Market - Live

The Board of Laurus Labs at its meeting held on 06 March 2025 has approved investment of an amount of Rs 83.30 crore in KRKA Pharma (KRKA), a joint venture of the Company. Further, KRKA d.d., Novo mesto, Slovenia (co-venturer) shall also invest an amount of Rs 86.70 crore in KRKA. Thereby, maintaining the existing shareholding ratio of 51:49 between KRKA d.d., Novo mesto and Laurus Labs. The purpose of this investment is to acquire land and to meet initial cost of setting up of a manufacturing facility for production of finished products for the new markets, including the Indian market. This investment aligns with the company's strategic growth plans and long-term business objectives. Powered by Capital Market - Live

Laurus Labs Ltd rose for a third straight session today. The stock is quoting at Rs 564.2, up 3.43% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.3% on the day, quoting at 22369.85. The Sensex is at 73855.47, up 1.19%. Laurus Labs Ltd has dropped around 11.4% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has dropped around 9.06% in last one month and is currently quoting at 19820.65, up 0.98% on the day. The volume in the stock stood at 18.59 lakh shares today, compared to the daily average of 27.02 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 565.1, up 3.1% on the day. Laurus Labs Ltd is up 37.39% in last one year as compared to a 0.46% fall in NIFTY and a 4.57% fall in the Nifty Pharma index.The PE of the stock is 117.78 based on TTM earnings ending December 24.Powered by Capital Market - Live

Laurus Labs Ltd is down for a fifth straight session today. The stock is quoting at Rs 546.75, down 9.03% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.87% on the day, quoting at 22830.85. The Sensex is at 75660.79, down 0.63%.Laurus Labs Ltd has lost around 1.82% in last one month.Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has eased around 5.47% in last one month and is currently quoting at 21427.1, down 3.06% on the day. The volume in the stock stood at 48.57 lakh shares today, compared to the daily average of 44.71 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 546.25, down 9.02% on the day. Laurus Labs Ltd jumped 39.28% in last one year as compared to a 4.2% rally in NIFTY and a 11.87% spurt in the Nifty Pharma index.The PE of the stock is 129.77 based on TTM earnings ending December 24.Powered by Capital Market - Live

Laurus Labs Ltd is up for a third straight session today. The stock is quoting at Rs 638.45, up 1.16% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.41% on the day, quoting at 23600.05. The Sensex is at 77920.62, down 0.45%. Laurus Labs Ltd has gained around 4.25% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has gained around 5.07% in last one month and is currently quoting at 21868.5, up 0.83% on the day. The volume in the stock stood at 18.29 lakh shares today, compared to the daily average of 42.52 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 639.8, up 1.03% on the day. Laurus Labs Ltd is up 60.15% in last one year as compared to a 7.61% jump in NIFTY and a 18.78% jump in the Nifty Pharma index.The PE of the stock is 136.31 based on TTM earnings ending December 24.Powered by Capital Market - Live